Proton pump inhibitors as a risk factor for hepatic encephalopathy and spontaneous bacterial peritonitis in patients with cirrhosis with ascites

Proton pump inhibitors (PPIs) may be a risk factor for hepatic encephalopathy (HE) in patients with cirrhosis, possibly through translocation of gut bacteria, which can also lead to spontaneous bacterial peritonitis (SBP). We examined the associations between PPIs and development of HE or SBP in patients with cirrhosis with ascites. We used data from three 1‐year trials of satavaptan for ascites control. We used Cox regression to compare HE and SBP rates between users and nonusers of PPIs. At inclusion, 39% of the 865 patients with cirrhosis with ascites used PPIs, 52% used them at some point during the follow‐up, and the proportion of current users was always in the 30%‐39% range. There were 189 first‐time HE episodes during the follow‐up, and the cumulative 1‐year risk was 31% for those who used PPIs at baseline versus 25% for those who did not. The confounder‐adjusted hazard ratio (HR) of HE for current PPI use versus current nonuse was 1.36 (95% confidence interval [CI], 1.01‐1.84). The HR for overt HE was higher (adjusted HR = 1.88; 95% CI, 1.21‐1.91). During the follow‐up, 86 patients developed SBP. The adjusted HR of SBP for current PPI users versus nonusers was 1.72 (95% CI, 1.10‐2.69). Conclusion: PPIs were used by 52% of this international cirrhosis cohort during a 1‐year period and was a risk factor for developing HE and SBP. These findings are consistent with the hypothesis that PPIs may increase translocation of gut bacteria. (Hepatology 2016;64:1265‐1272)

[1]  C. Tovo,et al.  Proton pump inhibitor use and spontaneous bacterial peritonitis in cirrhosis: An undesirable association? , 2015, Journal of hepatology.

[2]  F. Barreyro,et al.  Proton pump inhibitor therapy does not increase the incidence of spontaneous bacterial peritonitis in cirrhosis: a multicenter prospective study. , 2015, Journal of hepatology.

[3]  K. Reddy,et al.  Long-term use of antibiotics and proton pump inhibitors predict development of infections in patients with cirrhosis. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[4]  B. Kronenberger,et al.  Proton pump inhibitor treatment is associated with the severity of liver disease and increased mortality in patients with cirrhosis , 2015, Alimentary pharmacology & therapeutics.

[5]  S. Taylor-Robinson,et al.  Systems biology analysis of omeprazole therapy in cirrhosis demonstrates significant shifts in gut microbiota composition and function. , 2014, American journal of physiology. Gastrointestinal and liver physiology.

[6]  P. Hu,et al.  Association of Proton Pump Inhibitor Therapy with Hepatic Encephalopathy in Hepatitis B Virus-related Acute-on-Chronic Liver Failure , 2014, Hepatitis monthly.

[7]  D. Shawcross,et al.  Recent insights into the pathogenesis of hepatic encephalopathy and treatments , 2014, Expert review of gastroenterology & hepatology.

[8]  P. Deltenre,et al.  Role of proton pump inhibitors in the occurrence and the prognosis of spontaneous bacterial peritonitis in cirrhotic patients with ascites , 2013, Liver international : official journal of the International Association for the Study of the Liver.

[9]  H. Vilstrup,et al.  Satavaptan treatment for ascites in patients with cirrhosis: a meta-analysis of effect on hepatic encephalopathy development , 2013, Metabolic Brain Disease.

[10]  Adrian V. Hernández,et al.  Acid‐suppressive therapy is associated with spontaneous bacterial peritonitis in cirrhotic patients: A meta‐analysis , 2013, Journal of gastroenterology and hepatology.

[11]  K. Lapane,et al.  Proton pump inhibitors are associated with a high rate of serious infections in veterans with decompensated cirrhosis , 2012, Alimentary pharmacology & therapeutics.

[12]  D. Adler,et al.  Clostridium difficile-Associated Diarrhea and Proton Pump Inhibitor Therapy: A Meta-Analysis , 2012, The American Journal of Gastroenterology.

[13]  D. van Duin,et al.  Increased rate of spontaneous bacterial peritonitis among cirrhotic patients receiving pharmacologic acid suppression. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[14]  Ronald B. Geskus,et al.  ipw: An R Package for Inverse Probability Weighting , 2011 .

[15]  A. Gerbes,et al.  Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity , 2011, Gut.

[16]  Kyeong Ok Kim,et al.  Association between acid suppressive therapy and spontaneous bacterial peritonitis in cirrhotic patients with ascites , 2011, Scandinavian journal of gastroenterology.

[17]  Y. Chawla,et al.  Role of small intestinal bacterial overgrowth and delayed gastrointestinal transit time in cirrhotic patients with minimal hepatic encephalopathy. , 2010, Journal of hepatology.

[18]  A. Sanyal,et al.  Spectrum of neurocognitive impairment in cirrhosis: Implications for the assessment of hepatic encephalopathy , 2009, Hepatology.

[19]  R. Hoffmann,et al.  Association of Proton Pump Inhibitor Therapy With Spontaneous Bacterial Peritonitis in Cirrhotic Patients With Ascites , 2009, The American Journal of Gastroenterology.

[20]  N. Chavez-Tapia,et al.  Use and overuse of proton pump inhibitors in cirrhotic patients. , 2008, Medical science monitor : international medical journal of experimental and clinical research.

[21]  K. Obstein,et al.  Association between Proton Pump Inhibitor Use and Spontaneous Bacterial Peritonitis , 2008, Digestive Diseases and Sciences.

[22]  M. Hernán,et al.  Controlling for Time-dependent Confounding using Marginal Structural Models , 2004 .

[23]  G. Satten,et al.  Estimation of Integrated Transition Hazards and Stage Occupation Probabilities for Non‐Markov Systems Under Dependent Censoring , 2002, Biometrics.

[24]  R Fischer,et al.  Hepatic encephalopathy in chronic liver disease: a clinical manifestation of astrocyte swelling and low-grade cerebral edema? , 2000, Journal of hepatology.

[25]  A. Nakahara,et al.  [Proton-pump inhibitor]. , 1991, Nihon rinsho. Japanese journal of clinical medicine.

[26]  L. Ranek,et al.  Splanchnic galactose uptake in patients with cirrhosis during continuous infusion. , 1983, Clinical physiology.

[27]  S. Sherlock,et al.  The bacterial content of the small intestine in normal and cirrhotic subjects: relation to methionine toxicity. , 1957, Clinical science.